TY - JOUR
T1 - Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas
AU - Merchant, Melinda S.
AU - Bernstein, Donna
AU - Amoako, Martha
AU - Baird, Kristin
AU - Fleisher, Thomas A.
AU - Morre, Michel
AU - Steinberg, Seth M.
AU - Sabatino, Marianna
AU - Stroncek, Dave F.
AU - Venkatasan, Aradhana M.
AU - Wood, Bradford J.
AU - Wright, Matthew
AU - Zhang, Hua
AU - Mackall, Crystal L.
N1 - Funding Information:
This study was supported by the Intramural Research Program of the NIH.
Publisher Copyright:
©2016 AACR.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Purpose: Patients with metastatic or relapsed pediatric sarcomas receive cytotoxic regimens that induce high remission rates associated with profound lymphocyte depletion, but ultimately few survive long term. We administered adjuvant immunotherapy to patients with metastatic and recurrent pediatric sarcomas in an effort to improve outcomes. Experimental Design: Mononuclear cells were collected via apheresis, and tumor lysate was acquired via percutaneous biopsy at enrollment. Participants received standard antineoplastic therapy, followed by autologous lymphocytes, tumor lysate/keyhole limpet hemocyanin-pulsed dendritic cell vaccinations ± recombinant human IL7. Primary outcomes were toxicity and vaccine responses. Secondary outcomes were immune reconstitution, event-free survival, and overall survival (OS). Results: Forty-three patients enrolled and 29 received immunotherapy. The regimen was well tolerated. Intent-to-treat analysis demonstrated 5-year OS of 51% with significant differences based upon histologic group (63% vs. 0% for Ewing/rhabdomyosarcoma vs. other sarcomas) and response to standard therapy (74% no residual disease vs. 0% residual disease). Five-year intent-to-treat OS of patients with newly diagnosed metastatic Ewing/rhabdomyosarcoma was 77%, higher than previously reported in this population and higher than observed in a similar group treated with an earlier adjuvant immunotherapy regimen (25% 5-year OS). T-cell responses to autologous tumor lysate were identified in 62% of immunotherapy recipients, and survival was higher in those patients (73% 5-year OS with vs. 37% without immune response, P = 0.017). Immune reconstitution, measured by CD4 count recovery, was significantly enhanced in subjects treated with recombinant human IL7. Conclusions: Adjuvant immunotherapy may improve survival in patients with metastatic pediatric sarcoma.
AB - Purpose: Patients with metastatic or relapsed pediatric sarcomas receive cytotoxic regimens that induce high remission rates associated with profound lymphocyte depletion, but ultimately few survive long term. We administered adjuvant immunotherapy to patients with metastatic and recurrent pediatric sarcomas in an effort to improve outcomes. Experimental Design: Mononuclear cells were collected via apheresis, and tumor lysate was acquired via percutaneous biopsy at enrollment. Participants received standard antineoplastic therapy, followed by autologous lymphocytes, tumor lysate/keyhole limpet hemocyanin-pulsed dendritic cell vaccinations ± recombinant human IL7. Primary outcomes were toxicity and vaccine responses. Secondary outcomes were immune reconstitution, event-free survival, and overall survival (OS). Results: Forty-three patients enrolled and 29 received immunotherapy. The regimen was well tolerated. Intent-to-treat analysis demonstrated 5-year OS of 51% with significant differences based upon histologic group (63% vs. 0% for Ewing/rhabdomyosarcoma vs. other sarcomas) and response to standard therapy (74% no residual disease vs. 0% residual disease). Five-year intent-to-treat OS of patients with newly diagnosed metastatic Ewing/rhabdomyosarcoma was 77%, higher than previously reported in this population and higher than observed in a similar group treated with an earlier adjuvant immunotherapy regimen (25% 5-year OS). T-cell responses to autologous tumor lysate were identified in 62% of immunotherapy recipients, and survival was higher in those patients (73% 5-year OS with vs. 37% without immune response, P = 0.017). Immune reconstitution, measured by CD4 count recovery, was significantly enhanced in subjects treated with recombinant human IL7. Conclusions: Adjuvant immunotherapy may improve survival in patients with metastatic pediatric sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=84977068146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977068146&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-2550
DO - 10.1158/1078-0432.CCR-15-2550
M3 - Article
C2 - 26823601
AN - SCOPUS:84977068146
SN - 1078-0432
VL - 22
SP - 3182
EP - 3191
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 13
ER -